Carlos Castillo, MD
Hematology & Oncology · Jacksonville, FLNPI 1922095884
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.6% of the total across 140 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,423 and has fallen 81.4% since, to $452 in 2025. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.
Across 140 payments — averaging $33.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$500
- E.r. Squibb & Sons, L.L.C.$478
- Daiichi Sankyo Inc.$325
- Amgen$288
- AstraZeneca$256
- Genentech USA, Inc.$237
- plus $3K from 32 others
What the payments were for
- Food & beverage$4,26692%
- Education$3908%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $500 |
| E.r. Squibb & Sons, L.L.C. | 16 | $478 |
| Daiichi Sankyo Inc. | 7 | $325 |
| Amgen | 11 | $288 |
| AstraZeneca(2 entities) | 5 | $256 |
| Genentech USA, Inc. | 11 | $237 |
| Incyte Corporation | 2 | $199 |
| Eisai Inc. | 4 | $191 |
| Novartis | 6 | $188 |
| Pfizer | 12 | $170 |
| Seagen Inc. | 5 | $170 |
| Verastem, Inc. | 3 | $141 |
| GSK | 2 | $139 |
| UCB, Inc. | 3 | $131 |
| Pharmacosmos Therapeutics Inc. | 1 | $114 |
| Bristol Myers Squibb | 5 | $109 |
| Lilly USA, LLC | 4 | $107 |
| Array Biopharma Inc | 1 | $100 |
| Exelixis Inc. | 2 | $95 |
| Bayer | 2 | $89 |
| Merck | 4 | $69 |
| Tesaro, Inc. | 3 | $65 |
| Foundation Medicine, Inc. | 1 | $60 |
| Sanofi | 3 | $57 |
| Greenwich Biosciences, Inc. | 2 | $48 |
| Bard Peripheral Vascular, Inc. | 1 | $45 |
| EMD Serono, Inc. | 3 | $44 |
| Karyopharm Therapeutics Inc. | 2 | $42 |
| Lexicon Pharmaceuticals, Inc. | 2 | $36 |
| AMAG Pharmaceuticals, Inc. | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Stemline Therapeutics Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $21 |
| Boehringer Ingelheim | 1 | $15 |
| Aurobindo Pharma USA, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
| Aquestive Therapeutics, Inc. | 1 | $12 |
| Medtronic | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,656 in reported general payments places this provider in the 50th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CometriqCabozantinib S-Malate | 12 | $270,050 |
| Kisqali Femara Co-PackRibociclib Succinate/Letrozole | 14 | $150,439 |
| EliquisApixaban | 121 | $105,709 |
| XareltoRivaroxaban | 14 | $10,982 |
| Everolimus | 13 | $6,702 |
| Exemestane | 11 | $2,529 |
| Letrozole | 61 | $1,150 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 25 | $1,131 |
| Oxycodone Hcl | 14 | $655 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $621 |
| Tamoxifen Citrate | 28 | $522 |
| Hydroxyurea | 34 | $284 |
| Ondansetron OdtOndansetron | 12 | $264 |
| JantovenWarfarin Sodium | 18 | $228 |
| Hydromorphone Hcl | 12 | $219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cometriq | $95 | $270,05012 claims |
| PfizerEliquis | $170 | $105,709121 claims |
| Johnson & JohnsonXarelto | $500 | $10,98214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Jacksonville
- Edith PerezJacksonville$1.1M
- Vamsidhar VelchetiJacksonville$966K
- Arnab BasuJacksonville$440K
- Sikander AilawadhiJacksonville$179K
- James ForanJacksonville$164K
- Asher Chanan KhanJacksonville$109K
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.